NCT00004380已完成2 期
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
National Center for Research Resources (NCRR)0 个研究点目标入组 1 人开始时间: 1991年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma).
II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.
详细描述
PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months. If clinically indicated, therapy may be extended.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Progressive systemic sclerosis (scleroderma)
- •No pregnant or nursing women
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailureHeart Failure, CongestiveNCT00520806Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies1,161
已完成
2 期
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the LungOsteosarcomaEwing Sarcoma Family TumorsMalignant Fibrous HistiocytomaSarcoma, SynovialFibrosarcomaLeiomyosarcomaNCT00503295Oncolytics Biotech53
已完成
2 期
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungMetastatic or Recurrent Squamous Cell Carcinoma of the LungNCT00998192Oncolytics Biotech32
已完成
2 期
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaMetastatic MelanomaNCT00984464Oncolytics Biotech14
已完成
2 期
A Study of Reolysin For Patients With Advanced/Metastatic Breast CancerMetastatic Breast CancerNCT01656538Canadian Cancer Trials Group81